These results match with several reports which have demonstrated that TLR4/MyD88 blockade can suppress the cell proliferation of gastric cancer cell lines [55], hepatocarcinoma HEPG2 cells [56], human hepatoma cell lines [43], and head kidney lymphocytes in an infectious model [57]. Here, MYD88 is linked to hepatocellular carcinoma.